contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


finansinspektionen-flaggningsmeddelande-i-abliva-ab-18

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Abliva

Flaggningsmeddelande i Abliva ABAnmälan om förvärv eller överlåtelse av finansiella instrument. Emittent556595-6538 Abliva ABInstrumentSE0002575340 SharesInnehavarePharming Group N.V Före transaktione...

<div align="center"><div align="left" style="WIDTH: 575px; POSITION: relative"><div align="center" style="MARGIN-TOP: 10px; MARGIN-BOTTOM: 10px; MARGIN-RIGHT: 20px"><img border="0" src="http://mb.cision.com/Public/13135/0/aca45bcefa0046bb_org.gif" alt="Finansinspektionen"></div><div style="MARGIN-TOP: 10px"><img border="0" width="575" src="http://mb.cision.com/Public/13135/0/9287b61ccc5d0383_org.gif" alt="---" height="1"></div><div style="MARGIN-TOP: 20px; MARGIN-BOTTOM: 10px"><div style="MARGIN-LEFT: 30px; WIDTH: 472px; MARGIN-RIGHT: 30px"><h1>Flaggningsmeddelande i Abliva AB</h1>Anmälan om förvärv eller överlåtelse av finansiella instrument.<br><br><table width="512"><tbody><tr><td><b>Emittent</b></td><td class="tvalue">556595-6538 Abliva AB</td></tr><tr><td><b>Instrument</b></td><td class="tvalue">SE0002575340 Shares</td></tr><tr><td><b>Innehavare</b></td><td class="tvalue">Pharming Group N.V</td></tr><tr><td colspan="2">&nbsp;</td></tr><tr><td colspan="2"><b>Före transaktionen</b></td></tr><tr><td>Antal aktier</td><td class="tvalue">0</td></tr><tr><td>Antal rösträtter</td><td class="tvalue">0</td></tr><tr><td colspan="2">&nbsp;</td></tr><tr><td colspan="2"><b>Transaktionen</b></td></tr><tr><td>Skäl för flaggning</td><td class="tvalue">Köp</td></tr><tr><td>Datum</td><td class="tvalue">2025-02-07</td></tr><tr><td>Gränsvärde för antal aktier</td><td class="tvalue">66,67 %</td></tr><tr><td>Gränsvärde för rösträtter</td><td class="tvalue">66,67 %</td></tr><tr><td colspan="2">&nbsp;</td></tr><tr><td colspan="2"><b>Efter transaktionen:</b></td></tr><tr><td colspan="2">Antal</td></tr><tr><td>&nbsp;-&nbsp;aktier</td><td class="tvalue">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td>&nbsp;-&nbsp;direkt innehavda rösträtter</td><td class="tvalue">0</td></tr><tr><td>&nbsp;-&nbsp;indirekt innehavda rösträtter</td><td class="tvalue">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td colspan="2">Andel</td></tr><tr><td>&nbsp;-&nbsp;aktier</td><td class="tvalue">87,71357 %</td></tr><tr><td>&nbsp;-&nbsp;direkt innehavda rösträtter</td><td class="tvalue">0 %</td></tr><tr><td>&nbsp;-&nbsp;indirekt innehavda rösträtter</td><td class="tvalue">87,71357 %</td></tr><tr><td colspan="2"> </td></tr><tr><td colspan="3"><table><tbody><tr><td colspan="3">Fördelning av totalt innehav</td></tr><tr><td class="tlabel"></td><td class="tvalue1">Andel rösträtter</td><td class="tvalue2">Antal aktier genom:</td></tr><tr><td class="tlabel">Aktier, samt övriga instrument enligt LHF 4 kap. 2§ första stycket&nbsp;1</td><td class="tvalue1">87,71357&nbsp;%</td><td class="tvalue2">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td class="tlabel">Finansiella instrument enligt LHF 4 kap. 2§ första stycket&nbsp;2</td><td class="tvalue1"></td><td class="tvalue2"></td></tr><tr><td class="tlabel">Finansiella instrument enligt LHF 4 kap. 2§ första stycket&nbsp;3</td><td class="tvalue1"> </td><td class="tvalue2"></td></tr><tr><td class="tlabel">&nbsp;-&nbsp;Fysisk avvecklade</td><td class="tvalue1"></td><td class="tvalue2"></td></tr><tr><td class="tlabel">&nbsp;-&nbsp;Kontantavräknade</td><td class="tvalue1"></td><td class="tvalue2"></td></tr><tr><td colspan="3">&nbsp;</td></tr><tr><td class="tlabel">TOTALT</td><td class="tvalue1">87,71357&nbsp;%</td><td class="tvalue2">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td colspan="3">&nbsp;</td></tr><tr><td class="tlabel">Totalt antal rösträtter</td><td class="tvalue1"></td><td class="tvalue2"></td></tr></tbody></table></td></tr><tr><td colspan="2">&nbsp;</td></tr><tr><td colspan="2">Kedja av kontrollerande företag genom vilka rösterna innehas</td></tr><tr><td>&nbsp;-&nbsp;bolag</td><td class="tvalue">Pharming Technologies B.V</td></tr><tr><td>&nbsp;-&nbsp;antal rösträtter</td><td class="tvalue">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td>&nbsp;-&nbsp;andel av rösträtter</td><td class="tvalue">87,71357 %</td></tr><tr><td colspan="2">&nbsp;</td></tr><tr><td colspan="2">Koncernens samlade innehav</td></tr><tr><td>&nbsp;-&nbsp;antal rösträtter</td><td class="tvalue">1&nbsp;413&nbsp;841&nbsp;472</td></tr><tr><td>&nbsp;-&nbsp;andel av rösträtter</td><td class="tvalue">87,71357&nbsp;%</td></tr></tbody></table><br><br>Innehavare rapporterar flaggning via <a href="http://fi.se">fi.se</a>. Innehållet i flaggningsmeddelandet svarar innehavaren för.<br>Informationen skickades av Cision och finns även i FI:s databas Börsinformation, <a href="http://www.fi.se/borsinformation">www.fi.se/borsinformation</a>.</div></div><div style="MARGIN-TOP: 10px"><img border="0" width="575" src="http://mb.cision.com/Public/13135/0/9287b61ccc5d0383_org.gif" alt="---" height="1"></div></div></div>

Finansinspektionen: Flaggningsmeddelande i Abliva AB

Intervjuer i samband med Stockholm Corporate Finance 17:e Kapitalmarknadsdagar Life Science 2026

Return on capital (ROE, ROI, ROIC, RONIC)

Finansiella nyckeltal: EV/EBIT, EV/EBITA, EV/EBITDA och EV/Sales

Finanslingo enkelt förklarat: EBIT, EBITA och EBITDA 

Vad betyder ATH?